MADRIGAL PHARMACEUTICALS INC's ticker is MDGL and the CUSIP is 558868105. A total of 146 filers reported holding MADRIGAL PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is 0.91 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $225,648,303 | -36.8% | 1,545,113 | 0.0% | 1.30% | -37.1% |
Q2 2023 | $356,921,103 | -4.6% | 1,545,113 | 0.0% | 2.07% | +1.4% |
Q1 2023 | $374,319,075 | -16.5% | 1,545,113 | 0.0% | 2.04% | -24.4% |
Q4 2022 | $448,469,048 | +360.3% | 1,545,113 | +3.1% | 2.69% | +322.1% |
Q3 2022 | $97,434,000 | -9.2% | 1,499,213 | 0.0% | 0.64% | +4.8% |
Q2 2022 | $107,314,000 | -27.0% | 1,499,213 | 0.0% | 0.61% | -27.9% |
Q1 2022 | $147,103,000 | +15.8% | 1,499,213 | 0.0% | 0.84% | +36.7% |
Q4 2021 | $127,043,000 | +6.2% | 1,499,213 | 0.0% | 0.62% | +17.7% |
Q3 2021 | $119,622,000 | -18.1% | 1,499,213 | 0.0% | 0.52% | -18.1% |
Q2 2021 | $146,038,000 | -16.7% | 1,499,213 | 0.0% | 0.64% | -15.7% |
Q1 2021 | $175,363,000 | +5.2% | 1,499,213 | 0.0% | 0.76% | +21.0% |
Q4 2020 | $166,668,000 | -6.4% | 1,499,213 | 0.0% | 0.63% | -11.7% |
Q3 2020 | $178,002,000 | +4.8% | 1,499,213 | +0.0% | 0.71% | -5.1% |
Q2 2020 | $169,786,000 | +69.6% | 1,499,212 | 0.0% | 0.75% | +21.6% |
Q1 2020 | $100,087,000 | -6.1% | 1,499,212 | +28.2% | 0.62% | +8.8% |
Q4 2019 | $106,533,000 | +5.7% | 1,169,278 | 0.0% | 0.57% | -17.5% |
Q3 2019 | $100,815,000 | -17.7% | 1,169,278 | 0.0% | 0.69% | -17.6% |
Q2 2019 | $122,552,000 | -16.3% | 1,169,278 | 0.0% | 0.83% | -11.2% |
Q1 2019 | $146,464,000 | +11.1% | 1,169,278 | 0.0% | 0.94% | -13.1% |
Q4 2018 | $131,801,000 | -47.4% | 1,169,278 | 0.0% | 1.08% | -34.6% |
Q3 2018 | $250,377,000 | -23.4% | 1,169,278 | 0.0% | 1.65% | -32.9% |
Q2 2018 | $327,035,000 | +354.8% | 1,169,278 | +89.9% | 2.46% | +303.4% |
Q1 2018 | $71,906,000 | +27.2% | 615,684 | 0.0% | 0.61% | +24.3% |
Q4 2017 | $56,514,000 | +2075.3% | 615,684 | +965.9% | 0.49% | +2233.3% |
Q3 2017 | $2,598,000 | +176.7% | 57,762 | 0.0% | 0.02% | +162.5% |
Q2 2017 | $939,000 | +5.5% | 57,762 | 0.0% | 0.01% | +14.3% |
Q1 2017 | $890,000 | +3.4% | 57,762 | 0.0% | 0.01% | -12.5% |
Q4 2016 | $861,000 | +17.6% | 57,762 | 0.0% | 0.01% | +14.3% |
Q3 2016 | $732,000 | – | 57,762 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Tao Capital Management LP | 77,657 | $11,342 | 8.78% |
University of Wisconsin Foundation | 40,133 | $5,861,023 | 6.72% |
Paulson & Co. | 500,000 | $73,020,000 | 6.53% |
TCG Crossover Management, LLC | 179,917 | $26,275,079 | 3.87% |
Avoro Capital Advisors LLC | 1,555,000 | $227,092,200 | 3.54% |
Affinity Asset Advisors, LLC | 85,000 | $12,413,400 | 3.49% |
Ghost Tree Capital, LLC | 57,500 | $8,397,300 | 2.76% |
Lynwood Capital Management Inc. | 5,000 | $730,200 | 1.92% |
MPM BioImpact LLC | 40,859 | $5,967,048 | 1.59% |
Tri Locum Partners LP | 33,761 | $4,930,456 | 1.58% |